Sanofi Wins U.S. Breakthrough and Japan Orphan Status for Rilzabrutinib in Rare Anemia

Sanofi ( (SNY) ) just unveiled an update.

On February 9, 2026, Sanofi announced that its oral BTK inhibitor rilzabrutinib, marketed as Wayrilz for immune thrombocytopenia, received U.S. FDA breakthrough therapy designation and orphan drug status in Japan for treating warm autoimmune hemolytic anemia, a rare and potentially life-threatening autoimmune blood disorder. The dual designations, supported by data from the ongoing LUMINA 2 phase 2b and LUMINA 3 phase 3 trials, highlight the absence of targeted therapies for this condition and underscore rilzabrutinib’s broad rare-disease potential, reinforcing Sanofi’s strategic positioning in high‑value rare hematology and immune-mediated indications.

The most recent analyst rating on (SNY) stock is a Hold with a $51.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.

Spark’s Take on SNY Stock

According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.

The score is driven primarily by solid financial resilience and a constructive earnings outlook (growth, margin expansion, and buybacks). Valuation is supportive with a reasonable P/E and strong dividend, while weaker technical trend signals (below major moving averages and negative MACD) temper the overall rating.

To see Spark’s full report on SNY stock, click here.

More about Sanofi

Sanofi is an R&D-driven, AI-powered biopharmaceutical company focused on discovering and developing medicines and vaccines that leverage its deep expertise in immunology. Listed on Euronext and Nasdaq, the group targets serious immune-mediated and rare diseases, aiming to deliver both improved patient outcomes and sustainable growth through an innovative global pipeline.

Average Trading Volume: 3,418,272

Technical Sentiment Signal: Sell

Current Market Cap: $111.3B

For a thorough assessment of SNY stock, go to TipRanks’ Stock Analysis page.